tetano
Editor, Senior Moderator
Viruses
. 2022 Jan 14;14(1):144.
doi: 10.3390/v14010144.
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
Debashree Chatterjee[SUP] 1 [/SUP], Alexandra Tauzin[SUP] 1 2 [/SUP], Annemarie Laumaea[SUP] 1 2 [/SUP], Shang Yu Gong[SUP] 1 3 [/SUP], Yuxia Bo[SUP] 4 [/SUP], Aurélie Guilbault[SUP] 5 [/SUP], Guillaume Goyette[SUP] 1 [/SUP], Catherine Bourassa[SUP] 1 [/SUP], Gabrielle Gendron-Lepage[SUP] 1 [/SUP], Halima Medjahed[SUP] 1 [/SUP], Jonathan Richard[SUP] 1 2 [/SUP], Sandrine Moreira[SUP] 5 [/SUP], Marceline Côté[SUP] 4 [/SUP], Andrés Finzi[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes. Both these variants carry some mutations shared by other emerging variants. Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant. Similarly, the L452R mutation of B.1.617.2 (Delta) variant is present in A.2.5. In this study, we observed that these Spike variants bound better to the ACE2 receptor in a temperature-dependent manner. Pseudoviral particles bearing the Spike of Mu were similarly neutralized by plasma from vaccinated individuals than those carrying the Beta (B.1.351) and Delta (B.1.617.2) Spikes. Altogether, our results indicate the importance of measuring critical parameters such as ACE2 interaction, plasma recognition and neutralization ability of each emerging variant.
Keywords: ACE2; COVID-19; RBD; SARS-CoV-2; coronavirus; mRNA vaccines; spike glycoproteins; temperature; variants of concern; variants of interest; variants under monitoring.
. 2022 Jan 14;14(1):144.
doi: 10.3390/v14010144.
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
Debashree Chatterjee[SUP] 1 [/SUP], Alexandra Tauzin[SUP] 1 2 [/SUP], Annemarie Laumaea[SUP] 1 2 [/SUP], Shang Yu Gong[SUP] 1 3 [/SUP], Yuxia Bo[SUP] 4 [/SUP], Aurélie Guilbault[SUP] 5 [/SUP], Guillaume Goyette[SUP] 1 [/SUP], Catherine Bourassa[SUP] 1 [/SUP], Gabrielle Gendron-Lepage[SUP] 1 [/SUP], Halima Medjahed[SUP] 1 [/SUP], Jonathan Richard[SUP] 1 2 [/SUP], Sandrine Moreira[SUP] 5 [/SUP], Marceline Côté[SUP] 4 [/SUP], Andrés Finzi[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35062348
- DOI: 10.3390/v14010144
Abstract
The rapid emergence of SARS-CoV-2 variants is fueling the recent waves of the COVID-19 pandemic. Here, we assessed ACE2 binding and antigenicity of Mu (B.1.621) and A.2.5 Spikes. Both these variants carry some mutations shared by other emerging variants. Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant. Similarly, the L452R mutation of B.1.617.2 (Delta) variant is present in A.2.5. In this study, we observed that these Spike variants bound better to the ACE2 receptor in a temperature-dependent manner. Pseudoviral particles bearing the Spike of Mu were similarly neutralized by plasma from vaccinated individuals than those carrying the Beta (B.1.351) and Delta (B.1.617.2) Spikes. Altogether, our results indicate the importance of measuring critical parameters such as ACE2 interaction, plasma recognition and neutralization ability of each emerging variant.
Keywords: ACE2; COVID-19; RBD; SARS-CoV-2; coronavirus; mRNA vaccines; spike glycoproteins; temperature; variants of concern; variants of interest; variants under monitoring.